Dabigatraani (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dabigatraani" in Finnish language version.

refsWebsite

Global rank Finnish rank

7nih.gov

4^th place

12^th place

5worldcat.org

5^th place

9^th place

4doi.org

2^nd place

10^th place

1wiley.com

222^nd place

202^nd place

1drugs.com

399^th place

2,670^th place

1terveyskirjasto.fi

8,115^th place

35^th place

1fimea.fi

low place

165^th place

1web.archive.org

1^st place

1europa.eu

68^th place

51^st place

1semanticscholar.org

11^th place

2,329^th place

doi.org

dx.doi.org

S Sarah: The pharmacology and therapeutic use of dabigatran etexilate. The Journal of Clinical Pharmacology, 2013, 53. vsk, nro 1, s. 1–13. doi:10.1177/0091270011432169 ISSN 1552-4604 Artikkelin verkkoversio.^{[vanhentunut linkki]}
M Proietti, G Boriani: Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Therapeutics and Clinical Risk Management, 2018, 14. vsk, s. 1483–1488. PubMed:30174430 doi:10.2147/TCRM.S140377 ISSN 1176-6336 Artikkelin verkkoversio.
S Blech et al: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 2008, 36. vsk, nro 2, s. 386–399. PubMed:18006647 doi:10.1124/dmd.107.019083 ISSN 0090-9556 Artikkelin verkkoversio.
S Palta, R Saroa, A Palta: Overview of the coagulation system. Indian Journal of Anaesthesia, 2014, 58. vsk, nro 5, s. 515–523. PubMed:25535411 doi:10.4103/0019-5049.144643 ISSN 0019-5049 Artikkelin verkkoversio.

drugs.com

Dabigatran Etexilate Drugs.com. Viitattu 6.9.2019.

europa.eu

ema.europa.eu

Valmisteyhteenveto (PDF) ema.europa.eu.

fimea.fi

sic.fimea.fi

A Kalliokoski: Uusien oraalisten antikoagulanttien käyttöaiheet laajenevat - Sic! sic.fimea.fi. Arkistoitu 5.11.2019. Viitattu 7.9.2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

EHZ Wang et al: Stability of dabigatran etexilate in manufacturer’s blister pack, unit-dose packaging, and community pharmacy blister pack. The Canadian Journal of Hospital Pharmacy, 2015, 68. vsk, nro 1, s. 16–21. PubMed:25762815 ISSN 0008-4123 Artikkelin verkkoversio.
M Proietti, G Boriani: Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Therapeutics and Clinical Risk Management, 2018, 14. vsk, s. 1483–1488. PubMed:30174430 doi:10.2147/TCRM.S140377 ISSN 1176-6336 Artikkelin verkkoversio.
S Blech et al: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 2008, 36. vsk, nro 2, s. 386–399. PubMed:18006647 doi:10.1124/dmd.107.019083 ISSN 0090-9556 Artikkelin verkkoversio.
S Palta, R Saroa, A Palta: Overview of the coagulation system. Indian Journal of Anaesthesia, 2014, 58. vsk, nro 5, s. 515–523. PubMed:25535411 doi:10.4103/0019-5049.144643 ISSN 0019-5049 Artikkelin verkkoversio.

ncbi.nlm.nih.gov

EHZ Wang et al: Stability of dabigatran etexilate in manufacturer’s blister pack, unit-dose packaging, and community pharmacy blister pack. The Canadian Journal of Hospital Pharmacy, 2015, 68. vsk, nro 1, s. 16–21. PubMed:25762815 ISSN 0008-4123 Artikkelin verkkoversio.
M Proietti, G Boriani: Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Therapeutics and Clinical Risk Management, 2018, 14. vsk, s. 1483–1488. PubMed:30174430 doi:10.2147/TCRM.S140377 ISSN 1176-6336 Artikkelin verkkoversio.
S Palta, R Saroa, A Palta: Overview of the coagulation system. Indian Journal of Anaesthesia, 2014, 58. vsk, nro 5, s. 515–523. PubMed:25535411 doi:10.4103/0019-5049.144643 ISSN 0019-5049 Artikkelin verkkoversio.

semanticscholar.org

pdfs.semanticscholar.org

S Blech et al: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 2008, 36. vsk, nro 2, s. 386–399. PubMed:18006647 doi:10.1124/dmd.107.019083 ISSN 0090-9556 Artikkelin verkkoversio.

terveyskirjasto.fi

Pradaxa Duodecim - Terveyskirjasto. Viitattu 7.9.2019.^{[vanhentunut linkki]}

web.archive.org

A Kalliokoski: Uusien oraalisten antikoagulanttien käyttöaiheet laajenevat - Sic! sic.fimea.fi. Arkistoitu 5.11.2019. Viitattu 7.9.2019.

wiley.com

accp1.onlinelibrary.wiley.com

S Sarah: The pharmacology and therapeutic use of dabigatran etexilate. The Journal of Clinical Pharmacology, 2013, 53. vsk, nro 1, s. 1–13. doi:10.1177/0091270011432169 ISSN 1552-4604 Artikkelin verkkoversio.^{[vanhentunut linkki]}

worldcat.org

S Sarah: The pharmacology and therapeutic use of dabigatran etexilate. The Journal of Clinical Pharmacology, 2013, 53. vsk, nro 1, s. 1–13. doi:10.1177/0091270011432169 ISSN 1552-4604 Artikkelin verkkoversio.^{[vanhentunut linkki]}
EHZ Wang et al: Stability of dabigatran etexilate in manufacturer’s blister pack, unit-dose packaging, and community pharmacy blister pack. The Canadian Journal of Hospital Pharmacy, 2015, 68. vsk, nro 1, s. 16–21. PubMed:25762815 ISSN 0008-4123 Artikkelin verkkoversio.
M Proietti, G Boriani: Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. Therapeutics and Clinical Risk Management, 2018, 14. vsk, s. 1483–1488. PubMed:30174430 doi:10.2147/TCRM.S140377 ISSN 1176-6336 Artikkelin verkkoversio.
S Blech et al: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 2008, 36. vsk, nro 2, s. 386–399. PubMed:18006647 doi:10.1124/dmd.107.019083 ISSN 0090-9556 Artikkelin verkkoversio.
S Palta, R Saroa, A Palta: Overview of the coagulation system. Indian Journal of Anaesthesia, 2014, 58. vsk, nro 5, s. 515–523. PubMed:25535411 doi:10.4103/0019-5049.144643 ISSN 0019-5049 Artikkelin verkkoversio.